Advertisement
| artemisinin-based combination therapy: Artemisinin-Based and Other Antimalarials Guoqiao Li, Ying Li, Zelin Li, Meiyi Zeng, 2017-11-28 Artemisinin-Based and Other Antimalarials: Detailed Account of Studies by Chinese Scientists Who Discovered and Developed Them provides a historical and scientific background of the discovery and development of artemisinin, artemisinin derivatives, combination drugs and related chemicals. It is a historical document, a scientific treatise, and a fascinating description of innovative research on new drug development that is carried out under extremely difficult conditions. The book also includes detailed experiments, physical-chemical procedures, practical methodologies and clinical trials. It is a valuable reference for students and researchers in the fields of scientific history, medicine, pharmaceutical science, chemistry, pharmacology and toxicology. - Presents details of all stages of drug development, including in vitro experiment, animal exploratory studies, animal tests for toxicity, safety and efficacy followed by stages I, II, III and IV, safety and efficacy in human volunteers and patients with malaria - Provides many physical-chemical laboratory procedures, such as NMR, MS, HPLC and X-ray diffraction used in drug development - Includes practical methodology of clinical trials from many research centers and countries to demonstrate the importance of this discovery |
| artemisinin-based combination therapy: Saving Lives, Buying Time Institute of Medicine, Board on Global Health, Committee on the Economics of Antimalarial Drugs, 2004-09-09 For more than 50 years, low-cost antimalarial drugs silently saved millions of lives and cured billions of debilitating infections. Today, however, these drugs no longer work against the deadliest form of malaria that exists throughout the world. Malaria deaths in sub-Saharan Africaâ€currently just over one million per yearâ€are rising because of increased resistance to the old, inexpensive drugs. Although effective new drugs called artemisinins are available, they are unaffordable for the majority of the affected population, even at a cost of one dollar per course. Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance examines the history of malaria treatments, provides an overview of the current drug crisis, and offers recommendations on maximizing access to and effectiveness of antimalarial drugs. The book finds that most people in endemic countries will not have access to currently effective combination treatments, which should include an artemisinin, without financing from the global community. Without funding for effective treatment, malaria mortality could double over the next 10 to 20 years and transmission will intensify. |
| artemisinin-based combination therapy: Economic Analysis of Malaria Control in Sub-Saharan Africa Catherine Cavallaro Goodman, Paul W. Coleman, Anne Mills, 2000 |
| artemisinin-based combination therapy: Guidelines for the Treatment of Malaria World Health Organization, 2010 The purpose of this document is to provide comprehensible, global, evidence-based guidelines to help formulate policies and protocols for the treatment of malaria. Information is presented on the treatment of uncomplicated malaria, including disease in special groups (young children, pregnant women, people who are HIV positive, travellers from non-malaria endemic regions) and in complex emergency situations and severe malaria.--Publisher's description. |
| artemisinin-based combination therapy: Guidelines for the Treatment of Malaria. Third Edition World Health Organization, 2015-08-13 Malaria remains an important cause of illness and death in children and adults in countries in which it is endemic. Malaria control requires an integrated approach including prevention (primarily vector control) and prompt treatment with effective antimalarial agents. Malaria case management consisting of prompt diagnosis and effective treatment remains a vital component of malaria control and elimination strategies. Since the publication of the first edition of the Guidelines for the treatment of malaria in 2006 and the second edition in 2010 all countries in which P. falciparum malaria is endemic have progressively updated their treatment policy from use of ineffective monotherapy to the currently recommended artemisinin-based combination therapies (ACT). This has contributed substantially to current reductions in global morbidity and mortality from malaria. Unfortunately resistance to artemisinins has arisen recently in P. falciparum in South-East Asia which threatens these gains. This third edition of the WHO Guidelines for the treatment of malaria contains updated recommendations based on a firmer evidence base for most antimalarial drugs and in addition include recommendation on the use of drugs to prevent malaria in groups at high risk. The Guidelines provide a framework for designing specific detailed national treatment protocols taking into account local patterns of resistance to antimalarial drugs and health service capacity. It provides recommendations on treatment of uncomplicated and severe malaria in all age groups all endemic areas in special populations and several complex situations. In addition on the use of antimalarial drugs as preventive therapy in healthy people living in malaria-endemic areas who are high risk in order to reduce morbidity and mortality from malaria. The Guidelines are designed primarily for policy-makers in ministries of health who formulate country-specific treatment guidelines. Other groups that may find them useful include health professionals and public health and policy specialists that are partners in health or malaria control and the pharmaceutical industry. The treatment recommendations in the main document are brief; for those who wish to study the evidence base in more detail a series of annexes is provided with references to the appropriate sections of the main document. |
| artemisinin-based combination therapy: Malaria Control During Mass Population Movements and Natural Disasters Program on Forced Migration and Health at the Mailman School of Public Health of Columbia University, National Research Council, Committee on Population, Roundtable on the Demography of Forced Migration, Holly A. Williams, Peter B. Bloland, 2003-01-16 Admittedly, the world and the nature of forced migration have changed a great deal over the last two decades. The relevance of data accumulated during that time period can now be called into question. The roundtable and the Program on Forced Migration at the Mailman School of Public Health of Columbia University have commissioned a series of epidemiological reviews on priority public health problems for forced migrants that will update the state of knowledge. Malaria Control During Mass Population Movements and Natural Disasters- the first in the series, provides a basic overview of the state of knowledge of epidemiology of malaria and public health interventions and practices for controlling the disease in situations involving forced migration and conflict. |
| artemisinin-based combination therapy: Hepatotoxicity Hyman J. Zimmerman, 1999 Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury. |
| artemisinin-based combination therapy: Management of Severe Malaria World Health Organization, 2000-04 Malaria continues to be a major health problem in many parts of the world, with over 2,400 million people in 100 countries at risk of infection. This handbook is an updated edition of 'Management of severe and complicated malaria', providing practical guidance on the diagnosis and management of severe falciparum malaria, a form of the disease that can have life-threatening complications if treatment is delayed. |
| artemisinin-based combination therapy: CDC Yellow Book 2020 Centers for Disease Control and Prevention (CDC), 2019 The definitive reference for travel medicine, updated for 2020 A beloved travel must-have for the intrepid wanderer. -Publishers Weekly A truly excellent and comprehensive resource. -Journal of Hospital Infection The CDC Yellow Book offers everything travelers and healthcare providers need to know for safe and healthy travel abroad. This 2020 edition includes: � Country-specific risk guidelines for yellow fever and malaria, including expert recommendations and 26 detailed, country-level maps � Detailed maps showing distribution of travel-related illnesses, including dengue, Japanese encephalitis, meningococcal meningitis, and schistosomiasis � Guidelines for self-treating common travel conditions, including altitude illness, jet lag, motion sickness, and travelers' diarrhea � Expert guidance on food and drink precautions to avoid illness, plus water-disinfection techniques for travel to remote destinations � Specialized guidelines for non-leisure travelers, study abroad, work-related travel, and travel to mass gatherings � Advice on medical tourism, complementary and integrative health approaches, and counterfeit drugs � Updated guidance for pre-travel consultations � Advice for obtaining healthcare abroad, including guidance on different types of travel insurance � Health insights around 15 popular tourist destinations and itineraries � Recommendations for traveling with infants and children � Advising travelers with specific needs, including those with chronic medical conditions or weakened immune systems, health care workers, humanitarian aid workers, long-term travelers and expatriates, and last-minute travelers � Considerations for newly arrived adoptees, immigrants, and refugees Long the most trusted book of its kind, the CDC Yellow Book is an essential resource in an ever-changing field -- and an ever-changing world. |
| artemisinin-based combination therapy: Global Report on Antimalarial Drug Efficacy and Drug Resistance , 2010 This report provides a comprehensive, global overview of antimalarial drug efficacy and the resistance of malaria parasites to the antimalarial medicines used between 2000 and June 2010. Policy-makers in national ministries of health will benefit from this document, as it provides both a global and a regional picture of the efficacy of the antimalarial medicines currently used in national treatment programmes. In addition, the report will be a reference for scientists, enhancing their understanding of the complexity of antimalarial drug resistance. |
| artemisinin-based combination therapy: Antimalarial Chemotherapy Philip J. Rosenthal, 2001-04-01 Philip Rosenthal, MD, and a panel of leading malaria experts drawn from academia, the military, and international health organizations survey the latest scientific understanding of antimalarial chemotherapy, emphasizing the molecular mechanisms of resistance and the description of important new targets. Their survey covers the current status of malarial and antimalarial chemotherapy, the relevant biology and biochemistry of malaria parasites, the antimalarial drugs currently available, new chemical approaches to chemotherapy, and possible new targets for chemotherapy. Comprehensive and cutting-edge, Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery clearly delineates all the basic and clinical research now addressing one of the world's major unresolved disease problems, work that is now powerfully driving the rapid pace of antimalarial drug discovery today. |
| artemisinin-based combination therapy: The Garki Project L. Molineaux, G. Gramiccia, 1980 |
| artemisinin-based combination therapy: Malaria: Drugs, Disease and Post-genomic Biology David Sullivan, Sanjeev Krishna, 2006-01-09 Despite rapid increases in knowledge, malaria continues to kill more than a million people each year and causes symptomatic disease in a further 300 million individuals. This volume brings some of the world's best investigators to describe recent advances in both the scientific and clinical aspects of malaria, and bridges between the two. |
| artemisinin-based combination therapy: World Malaria Report 2008 World Health Organization, 2008 Curious kids will delight in the joy of scientific discovery through the fifty fun activities in The Budding Scientist! This book is filled with great ways for you and your child to learn about how our world works. Create memories together as you make invisible ink, explore ice crystals, and investigate magnets. Perfect for children ages three to six, this fun-filled introduction to science features easy-to-follow instructions and easy-to-find materials that will help you satisfy your child’s natural curiosity. |
| artemisinin-based combination therapy: Global Technical Strategy for Malaria 2016-2030 World Health Organization, 2015-11-04 The World Health Organization's Global Technical Strategy for Malaria 2016- 2030 has been developed with the aim to help countries to reduce the human suffering caused by the world's deadliest mosquito-borne disease. Adopted by the World Health Assembly in May 2015 it provides comprehensive technical guidance to countries and development partners for the next 15 years emphasizing the importance of scaling up malaria responses and moving towards elimination. It also highlights the urgent need to increase investments across all interventions - including preventive measures diagnostic testing treatment and disease surveillance- as well as in harnessing innovation and expanding research. By adopting this strategy WHO Member States have endorsed the bold vision of a world free of malaria and set the ambitious new target of reducing the global malaria burden by 90% by 2030. They also agreed to strengthen health systems address emerging multi-drug and insecticide resistance and intensify national cross-border and regional efforts to scale up malaria responses to protect everyone at risk. |
| artemisinin-based combination therapy: World Malaria Report 2015 World Health Organization, 2016-01-30 The World Malaria Report 2015assesses global malaria disease trends and changes in the coverage and financing of malaria control programs between 2000 and 2015. It also summarizes progress towards international targets, and provides regional and country profiles that summarize trends in each WHO region and each country with malaria. The report is produced with the help of WHO regional and country offices, ministries of health in endemic countries, and a broad range of other partners. The data presented are assembled from the 96 countries and territories with ongoing malaria transmission, and a further five countries that have recently eliminated malaria. Most data are those reported for 2014 and 2015, although in some cases projections have been made into 2015, to assess progress towards targets for 2015. |
| artemisinin-based combination therapy: CDC Yellow Book 2018: Health Information for International Travel Centers for Disease Control and Prevention CDC, 2017-04-17 THE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018 As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel has never been greater. For both international travelers and the health professionals who care for them, the CDC Yellow Book 2018: Health Information for International Travel is the definitive guide to staying safe and healthy anywhere in the world. The fully revised and updated 2018 edition codifies the U.S. government's most current health guidelines and information for international travelers, including pretravel vaccine recommendations, destination-specific health advice, and easy-to-reference maps, tables, and charts. The 2018 Yellow Book also addresses the needs of specific types of travelers, with dedicated sections on: · Precautions for pregnant travelers, immunocompromised travelers, and travelers with disabilities · Special considerations for newly arrived adoptees, immigrants, and refugees · Practical tips for last-minute or resource-limited travelers · Advice for air crews, humanitarian workers, missionaries, and others who provide care and support overseas Authored by a team of the world's most esteemed travel medicine experts, the Yellow Book is an essential resource for travelers -- and the clinicians overseeing their care -- at home and abroad. |
| artemisinin-based combination therapy: World Malaria Report 2019 World Health Organization, 2019-08-28 The World Malaria Report 2019 provides a comprehensive update on global and regional malaria data and trends. The report tracks investments in malaria programs and research as well as progress across all intervention areas: prevention, diagnosis, treatment, elimination, and surveillance. It also includes dedicated chapters on the consequences of malaria on maternal infant and child health the High Burden to High Impact approach as well as biological threats to the fight against malaria. The 2019 report is based on information received from more than 80 countries and areas with ongoing malaria transmission. This information is supplemented by data from national household surveys and databases held by other organizations. |
| artemisinin-based combination therapy: Population and Health in Developing Countries: Population, health and survival at INDEPTH sites International Development Research Centre (Canada), INDEPTH Network, 2002 Population and Health in Developing Countries: Volume 1. Poulation, health, and survival at INDEPTH sites |
| artemisinin-based combination therapy: World Malaria Report 2018 World Health Organization, 2019-02-12 This year s report shows that after an unprecedented period of success in global malaria control progress has stalled. Data from 2015?2017 highlight that no significant progress in reducing global malaria cases was made in this period. There were an estimated 219 million cases and 435 000 related deaths in 2017. The World malaria report 2018 draws on data from 90 countries and areas with ongoing malaria transmission. The information is supplemented by data from national household surveys and databases held by other organizations. |
| artemisinin-based combination therapy: Towards Malaria Elimination Sylvie Manguin, Vas Dev, 2018-07-18 Towards Malaria Elimination - A Leap Forward was started to mark the occasion for renewed commitment to end malaria transmission for good (the WHO's call for Malaria Free World by 2030). This book is dedicated for the benefit of researchers, scientists, program and policy managers, students and anyone interested in malaria and other mosquito-borne diseases with the goal of sharing recent information on success stories, innovative control approaches and challenges in different regions of the world. Some main issues that emerged included multidrug-resistant malaria and pandemic risk, vaccines, cross-border malaria, asymptomatic parasite reservoir, the threat of Plasmodium vivax and Plasmodium knowlesi, insecticide resistance in Anopheles vectors and outdoor malaria transmission. This book is one little step forward to bring together in 17 chapters the experiences of malaria-expert researchers from five continents to present updated information on disease epidemiology and control at the national/regional level, highlighting the constraints, challenges, accomplishments and prospects of malaria elimination. |
| artemisinin-based combination therapy: Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, 2020-04-24 Among the many who serve in the United States Armed Forces and who are deployed to distant locations around the world, myriad health threats are encountered. In addition to those associated with the disruption of their home life and potential for combat, they may face distinctive disease threats that are specific to the locations to which they are deployed. U.S. forces have been deployed many times over the years to areas in which malaria is endemic, including in parts of Afghanistan and Iraq. Department of Defense (DoD) policy requires that antimalarial drugs be issued and regimens adhered to for deployments to malaria-endemic areas. Policies directing which should be used as first and as second-line agents have evolved over time based on new data regarding adverse events or precautions for specific underlying health conditions, areas of deployment, and other operational factors At the request of the Veterans Administration, Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis assesses the scientific evidence regarding the potential for long-term health effects resulting from the use of antimalarial drugs that were approved by FDA or used by U.S. service members for malaria prophylaxis, with a focus on mefloquine, tafenoquine, and other antimalarial drugs that have been used by DoD in the past 25 years. This report offers conclusions based on available evidence regarding associations of persistent or latent adverse events. |
| artemisinin-based combination therapy: World Malaria Report 2014 World Health Organization, 2015-07-07 The World malaria report 2014 summarizes information received from 97 malaria endemic countries and other sources and updates the analyses presented in 2013. It assesses global and regional malaria trends highlights progress made towards global targets and describes opportunities and challenges in controlling and eliminating the disease. Most of the data presented in this report are for 2013. |
| artemisinin-based combination therapy: Advances in Malaria Research Deepak Gaur, Chetan E. Chitnis, Virander S. Chauhan, 2016-12-27 Thoroughly reviews our current understanding of malarial biology Explores the subject with insights from post-genomic technologies Looks broadly at the disease, vectors of infection, and treatment and prevention strategies A timely publication with chapters written by global researchers leaders |
| artemisinin-based combination therapy: Genetics and Evolution of Infectious Diseases Michel Tibayrenc, 2024-07-19 Genetics and Evolution of Infectious Diseases, Third Edition discusses the evolving field of infectious diseases and their continued impact on the health of populations, especially in resource-limited areas of the world where they must confront the dual burden of death and disability due to infectious and chronic illnesses. Although substantial gains have been made in public health interventions for the treatment, prevention, and control of infectious diseases, in recent decades the world has witnessed the emergence of the human immunodeficiency virus (HIV) and the COVID-19 pandemic, increasing antimicrobial resistance, and the emergence of many new bacterial, fungal, parasitic, and viral pathogens. Fully updated and revised, this new edition presents the consequences of such diseases, the evolution of infectious diseases, the genetics of host-pathogen relationship, and the control and prevention strategies that are, or can be, developed. This book offers valuable information to biomedical researchers, clinicians, public health practitioners, decisions-makers, and students and postgraduates studying infectious diseases, microbiology, medicine, and public health that is relevant to the control and prevention of neglected and emerging worldwide diseases. - Takes an integrated approach to infectious diseases - Provides the latest developments in the field of infectious diseases - Focuses on the contribution of evolutionary and genomic studies for the study and control of transmissible diseases - Includes updated and revised contributions from leading authorities, along with six new chapters |
| artemisinin-based combination therapy: Drug Repurposing in Cancer Therapy Kenneth K.W. To, William C.S. Cho, 2020-07-29 Drug Repurposing in Cancer Therapy: Approaches and Applications provides comprehensive and updated information from experts in basic science research and clinical practice on how existing drugs can be repurposed for cancer treatment. The book summarizes successful stories that may assist researchers in the field to better design their studies for new repurposing projects. Sections discuss specific topics such as in silico prediction and high throughput screening of repurposed drugs, drug repurposing for overcoming chemoresistance and eradicating cancer stem cells, and clinical investigation on combination of repurposed drug and anticancer therapy. Cancer researchers, oncologists, pharmacologists and several members of biomedical field who are interested in learning more about the use of existing drugs for different purposes in cancer therapy will find this to be a valuable resource. - Presents a systematic and up-to-date collection of the research underpinning the various drug repurposing approaches for a quick, but in-depth understanding on current trends in drug repurposing research - Brings better understanding of the drug repurposing process in a holistic way, combining both basic and clinical sciences - Encompasses a collection of successful stories of drug repurposing for cancer therapy in different cancer types |
| artemisinin-based combination therapy: Tu Youyou And The Discovery Of Artemisinin: 2015 Nobel Laureate In Physiology Or Medicine Yi Rao, Daqing Zhang, Runhong Li, 2016-09-28 Nobel laureate Tu Youyou won the 2015 prize for Medicine/Physiology for the discovery of artemisinin, a drug therapy for malaria that has saved millions across the globe.This book traces the path of discovery beginning with Chairman Mao's 1964 instruction to Chinese researchers to find a cure for malaria, a disease that plagued the military and civilians alike in endemic regions. It chronicles the years of painstaking research to find effective anti-malarial drugs, and how an entry in a collection of traditional Chinese medicine prescriptions gave Tu Youyou the clue which led her to successfully extract artemisinin from the plant, Artemisia annua.Gathering together information from a variety of sources including first-hand accounts, this book describes the contributions of the many organisations, scientists, doctors and countless others who played a part in the process of discovery and clinical testing. It also provides insights into the challenges of carrying out such an extensive research project with limited resources during the upheavals of the Cultural Revolution. An inspirational read for young scientists.Includes the translation of Professor Tu Youyou's 2015 Nobel Lecture. |
| artemisinin-based combination therapy: Ethics and Drug Resistance: Collective Responsibility for Global Public Health Euzebiusz Jamrozik, Michael Selgelid, 2021-08-21 This Open Access volume provides in-depth analysis of the wide range of ethical issues associated with drug-resistant infectious diseases. Antimicrobial resistance (AMR) is widely recognized to be one of the greatest threats to global public health in coming decades; and it has thus become a major topic of discussion among leading bioethicists and scholars from related disciplines including economics, epidemiology, law, and political theory. Topics covered in this volume include responsible use of antimicrobials; control of multi-resistant hospital-acquired infections; privacy and data collection; antibiotic use in childhood and at the end of life; agricultural and veterinary sources of resistance; resistant HIV, tuberculosis, and malaria; mandatory treatment; and trade-offs between current and future generations. As the first book focused on ethical issues associated with drug resistance, it makes a timely contribution to debates regarding practice and policy that are of crucial importance to global public health in the 21st century. |
| artemisinin-based combination therapy: Antimalarial Natural Products A. Douglas Kinghorn, Heinz Falk, Simon Gibbons, Yoshinori Asakawa, Ji-Kai Liu, Verena M. Dirsch, 2022-01-02 This volume begins with a short history of malaria and follows with a summary of its biology. It then traces the fascinating history of the discovery of quinine for malaria treatment, and then describes quinine’s biosynthesis, its mechanism of action, and its clinical use, concluding with a discussion of synthetic antimalarial agents based on quinine’s structure. It also covers the discovery of artemisinin and its development as the source of the most effective current antimalarial drug, including summaries of its synthesis and biosynthesis, its mechanism of action, and its clinical use and resistance. A short discussion of other clinically used antimalarial natural products leads to a detailed treatment of additional natural products with significant antiplasmodial activity, classified by compound type. Although the search for new antimalarial natural products from Nature’s combinatorial library is challenging, it is very likely to yield new antimalarial drugs. This book thus ends by identifying ten natural products with development potential as clinical antimalarial agents. |
| artemisinin-based combination therapy: A Detailed Chronological Record of Project 523 and the Discovery and Development of Qinghaosu (Artemisinin) Zhang Jianfang, 2013 This is an account of a project in China carried out in secrecy from the Chinese people and the Western World during the tumultuous years of the Cultural Revolution. Project 523, as it was called, resulted in one of the most significant advances in the treatment of malaria since the discovery and first use of quinine over 300 years ago. The origin of the project was a request from the North Vietnamese Government to Mao Zedong in China, for assistance in managing chloroquine drug-resistant malaria affecting their military forces during the Vietnam-American war. Initially the project was directed by the Chinese military medical research authorities, but it became so large that civilian scientists were called upon to help. Ultimately, to accomplish this task, over 60 institutions and more than 500 scientists and other personnel scattered throughout mainland China became involved. This achievement is all the more remarkable because it was accomplished during the Cultural Revolution using obsolete equipment, and at a time when all regular research was halted, scientists were harassed and denigrated, and academic and intellectual activity was discouraged or even forbidden. The drug discovered - artemisinin from the plant Qinghao (Artemisia annua L) - is now the most widely used treatment for malaria in the world. |
| artemisinin-based combination therapy: World Malaria Report 2016 World Health Organization, 2017-05-09 The World Malaria Report 2016 summarizes information received from malaria-endemic countries and other sources and updates the analyses presented in the 2015 report. The World Malaria Report is WHO's flagship malaria publication released each year in December. It assesses global and regional malaria trends, highlights progress towards global targets, and describes opportunities and challenges in controling and eliminating the disease. Most of the data presented in this report is for 2015. |
| artemisinin-based combination therapy: Vector-Borne Diseases David Claborn, Sujit Bhattacharya, Syamal Roy, 2020-06-03 Vector-Borne Diseases - Recent Developments in Epidemiology and Control utilizes the unique capabilities of open-access publishing to share exciting developments in the biology, diagnosis, and treatment of diseases spread by arthropods. From malaria to dengue to leishmaniasis, the diseases addressed in this book continue to present threats to the life and well-being of millions around the world. The international cast of writers published here provide specific insight into a full spectrum of diseases spread by insects and their close relatives. |
| artemisinin-based combination therapy: Rolling Back Malaria World Bank, 2005 There are more than 1.1 million deaths per year from malaria, mostly among children less than five years old. The disease is preventable and curable with available technologies, but , in the absence of strong and sustained malaria control efforts, coverage with effective interventions is low, particularly among the poor. Malaria impairs economic growth and human development in many of the World Bank's client countries, particularly in Sub-Saharan Africa. The Bank has the capacity to do a lot more than it has in malaria control, including financing, policy advice, and implementation support. It will support countries to develop and implement programs to (i) cost-effectively reduce morbidity, productivity losses in multiple sectors, and mortality due to malaria, particularly among the poor and among children and pregnant women; and (ii) address the challenges of regional and global public goods. |
| artemisinin-based combination therapy: An Overview of Tropical Diseases Amidou Samie, 2015-12-02 Tropical diseases affect millions of people throughout the world and particularly in the developing countries. The millennium development goals had specifically targeted HIV/AIDS and Malaria for substantial reduction as well as Tuberculosis while many other tropical diseases have been neglected. The new sustainable development goals have not made such distinction and have targeted all diseases for elimination for the improvement of the quality of life of human beings on earth. The present book was developed to provide an update on issues relevant to the treatment of selected tropical diseases such as tuberculosis, malaria, leishmaniasis, schistosomiasis and ectoparasites such as chiggers which are widely distributed throughout the world. The control of these infections has been hampered by the development of drug resistance and the lack of the development of new and more effective drugs. The understanding of the biochemical processes underlying drug activity is therefore essential for the potential elimination of these infections. |
| artemisinin-based combination therapy: SARS , 2004-01-01 SARS is a newly identified human infection caused by a corona virus unlike any other known human or animal virus in its family. The analysis of epidemiological information obtained from the sites of the outbreaks of SARS is still underway but the overall case fatality ratio is known to approach 11% although the rate among the elderly is much higher. Currently the major challenges for the treatment of SARS are: the source of the SARS virus and mode of transmission are still not well understood; there are problems with diagnostic tools; there is no effective treatment; and there is no vaccine for SARS. The above-mentioned difficulties and challenges have motivated national authorities health workers and scientists to explore the potential of complementary treatment. The results of research on integrated treatment with TCM and Western medicine showed that it is safe and that it also has some potential clinical benefits. Therefore the experts suggested that records of such experience could serve as reference material for treatment of SARS in the future. This publication is intended to share experience in the complementary treatment of SARS patients; share the experience of clinical studies in the field of traditional medicine for treatment of SARS between the physicians and researchers; and to further encourage and promote the quality of research in the filed of traditional medicine. |
| artemisinin-based combination therapy: Immunity and Inflammation in Health and Disease Shampa Chatterjee, Wolfgang Jungraithmayr, Debasis Bagchi, 2017-08-31 Immunity and Inflammation in Health and Disease: Emerging Roles of Nutraceuticals and Functional Foods in Immune Support provides a comprehensive description of the various pathways by which the vertebrate immune system works, the signals that trigger immune response and how fnew and novel nutraceuticals and functional foods, can be used to contain inflammation and also to boost immunity and immune health. Inflammation is a tool to fight pathogens and the vertebrate immune system has a very complex network of cells to achieve this. However inflammation that goes awry is also the leding cause of several diseases ranging from cardiovascular diseases to diabetes. This book covers the entire gamut from the various cellular players in the inflammation-immune response to its ramifications in terms of protection against pathogens as well as in onset of metabolic, aging and auto-immune related diseases. Finally, the balancing role of dietary nutrients between host defence and immune support is also showcased. The first three scetions explain the various components of the immune system and their modes of activation. The fourth section deals with the ramifications of a robust and execessive inflammatory response. The fifth section is focused on the association between nutrition and immunity and how deficiencies in certain nutrients may affect immunocompetence. The sixth section chapters represent a vision of paradigm shifts within the field and discusses possible future directions. This bool will be a valuable reference for researchers studying immune health either in academia, or in the nutraceutical or functional food industries. Product developers in nutraceutical, supplement, functional food, and health food companies will also appreciate the information presented here. - Conceptualizes the key features in natural products which can boost immune function and immune health - Explains the intricate mechanistic aspects and balance behind immune health - Presents the pathophysiology of several diseases associated with immune system disruption |
| artemisinin-based combination therapy: Threshold Analysis Jurek Kozlowski, James T. Hughes, Rosalind Brown, 1972 |
| artemisinin-based combination therapy: The Selection and Use of Essential Medicines WHO Expert Committee on the Selection and Use of Essential Medicines, 2004 This report presents the recommendations of the WHO Expert Committee responsible for updating the WHO Model List of Essential Medicines. The first part contains a progress report on the new procedures for updating the Model List and the development of the WHO Essential Medicines Library. It continues with a section on changes made in revising the Model List followed by a review of some sections such as hypertensive medicines and fast track procedures for deleting items. Annexes include the 13th version of the Model List and items on the list sorted according to their 5-level Anatomical Therapeutic Chemical classification codes. |
| artemisinin-based combination therapy: World malaria report 2017 World Health Organization, 2018-02-12 The World Malaria Report 2017 presents a comprehensive state of play in global progress in the fight against malaria up to the end of 2016. It tracks progress in investments in malaria programs and research, malaria prevention, diagnosis and treatment, surveillance, trends in malaria disease burden, malaria elimination, and threats in tackling malaria and safeguarding the investments made. The report draws on data from 91 countries and areas with ongoing malaria transmission. The information is supplemented by data from national household surveys and databases held by other organizations. This year's report shows that after an unprecedented period of success in global malaria control, progress has stalled. In 2016, there were an estimated 216 million cases of malaria, an increase of about 5 million cases over 2015. Deaths reached 445,000, a similar number to the previous year. |
| artemisinin-based combination therapy: Malaria in Africa Olaf Müller, 2011 About half of the world's population is still at risk for contracting malaria, and the main disease burden is now in sub-Saharan Africa (SSA). As a result of the activities of a number of new and powerful Global Health Initiatives, malaria morbidity and mortality has recently started to decrease and the idea of eradication has re-emerged. This book provides a comprehensive update on the recent developments of the epidemiology of malaria and of existing strategies and tools for malaria control and elimination in Africa, which is discussed in the context of the long global history of malaria control. The main message is that the ambitious Global Malaria Action Plan of RBM will fail without serious efforts to systematically and massively strengthen the health systems of African countries.--Back cover. |
Artemisinin resistance and artemisinin-based combination …
WHO recommends artemisinin-based combination therapies (ACTs) for the treatment of uncomplicated malaria caused by Plasmodium falciparum. ACTs have been an integral part of …
Artemisinin-based combination therapies: a vital tool in
Abstract | Plasmodium falciparum resistance to chloroquine and sulphadoxine–pyrimeth-amine has led to the recent adoption of artemisinin-based combination therapies (ACTs) as the first …
Artemisinin-Based Combination Therapy: Knowledge and
Artemisinin-based Combination Therapy (ACT), a drug that possesses the most rapid action against Plasmo-dium falciparum malaria, became the recommended treat-ment for …
Optimization of a new artemisinin-based combination therapy …
This work aimed to develop a new fixed-dose combination tablet (FDCT) containing artesunate (ART) 50 mg and piperaquine 320 mg for enhanced malaria parasites treatment. Firstly, the …
Triple artemisinin-based combination therapies versus …
Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide efective treatment …
Efficacy and safety of artemisinin-based combination therapy, …
cacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania. Malaria Journal, 2018, 17, pp.369. …
Triple artemisinin-based combination therapy (TACT): …
Artemisinin-Based Combination Therapy (ACT) is recognized for its cost-efective-ness, lower likelihood of adverse events, and widespread acceptance by patients and healthcare …
Biochemical Effect of Artemisin-based Combination Therapy
artemisinin-based combination therapy (ACT) is expected to allow fewer opportunities for the progress of drug resistance as the artemisinin component kills the majority of parasites at the …
Artemisinin resistance and artemisinin-based combination …
Artemisinin-based combination therapies (ACTs) are recommended by WHO as the first-and second-line treatment for uncomplicated P. falciparum malaria as well as for chloroquine …
WHO Position Statement (June 2012) - World Health …
The World Health Organization (WHO) recommends artemisinin-based combination therapy (ACT) for the treatment of uncomplicated malaria due to Plasmodium falciparum (P. …
Artemisinin resistance and artemisinin-based combination …
Artemisinin resistance and artemisinin-based combination therapy efficacy STATUS OF ANTIMALARIAL DRUG EFFICACY (2010– 2018) Plasmodium resistance to antimalarial …
Is triple artemisinin-based combination therapy necessary for ...
TACTs are developed to counter the increasing problem of Plasmodium falciparum resistance to artemisinins and their partner drugs in artemisinin combination therapies (ACTs).
Preventing antimalarial drug resistance with triple artemisinin …
Triple artemisinin-based combination therapies (TACTs) which combine artemisinin derivatives with two partner drugs are efficacious and well tolerated in clinical trials, including in areas...
The current use of the artemisinin-based Combination …
Artemisinin-based combination therapies (ACTs) are the choice medicines for malaria treatment. The preferences, tolerability, and cost of these ACTs are largely understudied.
Artemisinin and artemisinin-based combination therapy …
Nearly all malaria-endemic countries recommend artemisinin-based combination therapies (ACTs) for the treatment of uncomplicated P. falciparum. TES results for ACTs in the treatment of P. …
Triple artemisinin-based combination therapies for malaria: …
Artemisinin-based combination . therapies (ACTs) serve as the front-line treatment against malaria. Substantial evidence indicates that treatment failure of the 3-day ACT course in the …
Is triple artemisinin-based combination therapy necessary for ...
At least three artemisinin-based combination therapies are still highly efficacious (ie, cure rate of >95% of patients): artesunate– mefloquine and artesunate– pyronaridine in Cambodia, Laos, …
Artemisinin and artemisinin-based combination therapy …
Artemisinin resistance1 is defined as delayed parasite clearance following treatment with an artesunate monotherapy or with an artemisinin-based combination therapy (ACT).
Pre-existing partner-drug resistance to artemisinin …
In this study, a consortium of modelling groups estimated the speed of selection of artemisinin resistance under a range of epidemiological settings with diferent first-line artemisinin …
Is triple artemisinin-based combination therapy necessary for ...
Is triple artemisinin-based combination therapy necessary for uncomplicated malaria? The impact of vaccines in limiting childhood morbidity and mortality due to infectious disease, especially in …
Artemisinin resistance and artemisinin-based combination …
WHO recommends artemisinin-based combination therapies (ACTs) for the treatment of uncomplicated malaria caused by Plasmodium falciparum. ACTs have been an integral part of …
Artemisinin-based combination therapies: a vital tool in
Abstract | Plasmodium falciparum resistance to chloroquine and sulphadoxine–pyrimeth-amine has led to the recent adoption of artemisinin-based combination therapies (ACTs) as the first …
Artemisinin-Based Combination Therapy: Knowledge and
Artemisinin-based Combination Therapy (ACT), a drug that possesses the most rapid action against Plasmo-dium falciparum malaria, became the recommended treat-ment for …
Optimization of a new artemisinin-based combination …
This work aimed to develop a new fixed-dose combination tablet (FDCT) containing artesunate (ART) 50 mg and piperaquine 320 mg for enhanced malaria parasites treatment. Firstly, the …
Triple artemisinin-based combination therapies versus …
Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide efective treatment …
Efficacy and safety of artemisinin-based combination …
cacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania. Malaria Journal, 2018, 17, pp.369. …
Triple artemisinin-based combination therapy (TACT): …
Artemisinin-Based Combination Therapy (ACT) is recognized for its cost-efective-ness, lower likelihood of adverse events, and widespread acceptance by patients and healthcare …
Biochemical Effect of Artemisin-based Combination Therapy
artemisinin-based combination therapy (ACT) is expected to allow fewer opportunities for the progress of drug resistance as the artemisinin component kills the majority of parasites at the …
Artemisinin resistance and artemisinin-based combination …
Artemisinin-based combination therapies (ACTs) are recommended by WHO as the first-and second-line treatment for uncomplicated P. falciparum malaria as well as for chloroquine …
WHO Position Statement (June 2012) - World Health …
The World Health Organization (WHO) recommends artemisinin-based combination therapy (ACT) for the treatment of uncomplicated malaria due to Plasmodium falciparum (P. …
Artemisinin resistance and artemisinin-based combination …
Artemisinin resistance and artemisinin-based combination therapy efficacy STATUS OF ANTIMALARIAL DRUG EFFICACY (2010– 2018) Plasmodium resistance to antimalarial …
Is triple artemisinin-based combination therapy necessary …
TACTs are developed to counter the increasing problem of Plasmodium falciparum resistance to artemisinins and their partner drugs in artemisinin combination therapies (ACTs).
Preventing antimalarial drug resistance with triple artemisinin …
Triple artemisinin-based combination therapies (TACTs) which combine artemisinin derivatives with two partner drugs are efficacious and well tolerated in clinical trials, including in areas...
The current use of the artemisinin-based Combination …
Artemisinin-based combination therapies (ACTs) are the choice medicines for malaria treatment. The preferences, tolerability, and cost of these ACTs are largely understudied.
Artemisinin and artemisinin-based combination therapy …
Nearly all malaria-endemic countries recommend artemisinin-based combination therapies (ACTs) for the treatment of uncomplicated P. falciparum. TES results for ACTs in the treatment of P. …
Triple artemisinin-based combination therapies for malaria: …
Artemisinin-based combination . therapies (ACTs) serve as the front-line treatment against malaria. Substantial evidence indicates that treatment failure of the 3-day ACT course in the …
Is triple artemisinin-based combination therapy necessary …
At least three artemisinin-based combination therapies are still highly efficacious (ie, cure rate of >95% of patients): artesunate– mefloquine and artesunate– pyronaridine in Cambodia, Laos, …
Artemisinin and artemisinin-based combination therapy …
Artemisinin resistance1 is defined as delayed parasite clearance following treatment with an artesunate monotherapy or with an artemisinin-based combination therapy (ACT).
Pre-existing partner-drug resistance to artemisinin …
In this study, a consortium of modelling groups estimated the speed of selection of artemisinin resistance under a range of epidemiological settings with diferent first-line artemisinin …
Is triple artemisinin-based combination therapy necessary …
Is triple artemisinin-based combination therapy necessary for uncomplicated malaria? The impact of vaccines in limiting childhood morbidity and mortality due to infectious disease, especially in …
